Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 20/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 12/20 | 0.73 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6320380 | 1.00 | ADRB3 (0.73) | ADRB3ADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL6321064 | 0.88 | ADRB3 (0.64) | ADRB3ADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL6321079 | 0.88 | ADRB3 (0.64) | ADRB3ADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL6329124 | 0.85 | ADRB3 (0.74) | ADRB3 | |
| Hydrochloric Acid SCHEMBL6321271 | 0.85 | ADRB3 (0.74) | ADRB3 | |
| Hydrochloric Acid SCHEMBL6322184 | 0.85 | ADRB3 (0.74) | ADRB3 | |
| SCHEMBL6322913 | 0.85 | ADRB3 (0.61) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6322905 | 0.85 | ADRB3 (0.61) | ADRB3ADRB2ADRB1 | |
| SCHEMBL7672279 | 0.84 | ADRB3 (1.00) | ADRB3ADRB2ADRB1 | |
| SCHEMBL7672281 | 0.84 | ADRB3 (1.00) | ADRB3ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288187-A1 | Inhibitor development for 4-hydroxyphenylpyruvate dioxygenase, employing tyrosinemia 1 as a model for human diseases mediated by 2-oxoacid utilizing dioxygenases | ROCKEFELLER UNIVERSITY, THE | 2005-12-29 | — | — | US | disclosed |
| US-20050043371-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20030181726-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043371-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885ADRB2 3/4885ADRB1 1/4885 |
| US-20030181726-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885ADRB2 3/4885ADRB1 1/4885 |
| US-20050288187-A1 | Inhibitor development for 4-hydroxyphenylpyruvate dioxygenase, employing tyrosinemia 1 as a model for human diseases mediated by 2-oxoacid utilizing dioxygenases | HPD, TH, PDXK | ADRB3 2897/4885ADRB2 3702/4885ADRB1 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.